Clinical trials in cystic fibrosis

Gerd Döring, J. Stuart Elborn, Marie Johannesson, Hugo de Jonge, Matthias Griese, Alan Smyth, Harry Heijerman

Research output: Contribution to journalLiterature review

41 Citations (Scopus)

Abstract

In patients with cystic fibrosis (CF), clinical trials are of paramount importance. Here, the current status of drug development in CF is discussed and future directions highlighted. Methods for pre-clinical testing of drugs with potential activity in CF patients including relevant animal models are described. Study design options for phase II and phase III studies involving CF patients are provided, including required patient numbers, safety issues and surrogate end point parameters for drugs, tested for different disease manifestations. Finally, regulatory issues for licensing new therapies for CF patients are discussed, including new directives of the European Union and the structure of a European clinical trial network for clinical studies involving CF patients is proposed.
Original languageEnglish
Pages (from-to)85-99
Number of pages15
JournalJournal of Cystic Fibrosis
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 2007

Keywords

  • drug development
  • pre-clinical drug testing
  • animal models
  • surrogate end points
  • safety issues
  • drug licensing
  • european clinical trial network for CF
  • Consesnsus study Group

Fingerprint Dive into the research topics of 'Clinical trials in cystic fibrosis'. Together they form a unique fingerprint.

Cite this